These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 16575474)

  • 21. Different cellular drug resistance profiles in childhood lymphoblastic and non-lymphoblastic leukemia: a preliminary report.
    Kaspers GJ; Kardos G; Pieters R; Van Zantwijk CH; Klumper E; Hählen K; de Waal FC; van Wering ER; Veerman AJ
    Leukemia; 1994 Jul; 8(7):1224-9. PubMed ID: 8035616
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial.
    Mitchell CD; Richards SM; Kinsey SE; Lilleyman J; Vora A; Eden TO;
    Br J Haematol; 2005 Jun; 129(6):734-45. PubMed ID: 15952999
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
    Kwok CS; Kham SK; Ariffin H; Lin HP; Quah TC; Yeoh AE
    Pediatr Blood Cancer; 2006 Sep; 47(3):299-304. PubMed ID: 16302217
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of children with acute lymphoblastic leukemia in India using a BFM protocol.
    Bajel A; George B; Mathews V; Viswabandya A; Kavitha ML; Srivastava A; Chandy M
    Pediatr Blood Cancer; 2008 Nov; 51(5):621-5. PubMed ID: 18688848
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Prognostic factors for childhood acute non-mature B-lymphoblastic leukemia].
    Jiang H; Gu LJ; Xue HL; Tang JY; Chen J; Pan C; Chen J; Xu C; Dong L; Zhou M
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):290-4. PubMed ID: 18554450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of dose-reduced Medac L-asparaginase on coagulation in trial ALL-BFM 2000.
    Attarbaschi A; Mann G; Kronberger M; Witt V; Gadner H; Dworzak M
    Klin Padiatr; 2003; 215(6):321-6. PubMed ID: 14677096
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse.
    Hijiya N; Stewart CF; Zhou Y; Campana D; Coustan-Smith E; Rivera GK; Relling MV; Pui CH; Gajjar A
    Cancer; 2008 May; 112(9):1983-91. PubMed ID: 18318429
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Acute lymphoblastic leukemia in children with initial leucocytosis above 50,000/mm3: summary of treatment results of Polish Pediatric Leukemia/Lymphoma Study Group].
    Skoczeń S; Balwierz W; Moryl-Bujakowska A; Pawińska K; Luszczyńska A; Balcerska A; Płoszyńska A; Chybicka A; Dobaczewski G; Juszczak K; Wachowiak J; Derwich K; Kowalczyk J; Wiśniewska-Slusarz H; Matysiak M; Krauze A; Pawelec K; Sońta-Jakimczyk D; Tomaszewska R; Wysocki M; Styczyńskii J; Swiatkiewicz V;
    Przegl Lek; 2006; 63(1):11-4. PubMed ID: 16892892
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Prognostic value of the initial response to corticosteroids for children with acute lymphoblastic leukemia].
    Klimza MJ; Sońta-Jakimczyk DJ
    Wiad Lek; 2005; 58(11-12):622-5. PubMed ID: 16594471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A role for altered microtubule polymer levels in vincristine resistance of childhood acute lymphoblastic leukemia xenografts.
    Ong V; Liem NL; Schmid MA; Verrills NM; Papa RA; Marshall GM; Mackenzie KL; Kavallaris M; Lock RB
    J Pharmacol Exp Ther; 2008 Feb; 324(2):434-42. PubMed ID: 17986648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Consolidation therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of cytosine arabinoside, epipodophyllotoxins and cyclophosphamide.
    Estlin EJ; Yule SM; Lowis SP
    Cancer Treat Rev; 2001 Dec; 27(6):339-50. PubMed ID: 11908927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic effectiveness of the ALL-XH-99 protocol for childhood acute lymphoblastic leukemia.
    Wang YR; Jin RM; Xu JW; Xiao Y; Zhou DF; Zhang ZQ
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Feb; 10(1):1-4. PubMed ID: 18289459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation between high vascular endothelial growth factor-A serum levels and treatment outcome in patients with standard-risk acute lymphoblastic leukemia: a report from Children's Oncology Group Study CCG-1962.
    Avramis IA; Panosyan EH; Dorey F; Holcenberg JS; Avramis VI;
    Clin Cancer Res; 2006 Dec; 12(23):6978-84. PubMed ID: 17145817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. No advantage of dexamethasone over prednisolone for the outcome of standard- and intermediate-risk childhood acute lymphoblastic leukemia in the Tokyo Children's Cancer Study Group L95-14 protocol.
    Igarashi S; Manabe A; Ohara A; Kumagai M; Saito T; Okimoto Y; Kamijo T; Isoyama K; Kajiwara M; Sotomatsu M; Sugita K; Sugita K; Maeda M; Yabe H; Kinoshita A; Kaneko T; Hayashi Y; Ikuta K; Hanada R; Tsuchida M
    J Clin Oncol; 2005 Sep; 23(27):6489-98. PubMed ID: 16170158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3/HOX11L2 gene expression on outcome.
    Ballerini P; Landman-Parker J; Cayuela JM; Asnafi V; Labopin M; Gandemer V; Perel Y; Michel G; Leblanc T; Schmitt C; Fasola S; Hagemejier A; Sigaux F; Auclerc MF; Douay L; Leverger G; Baruchel A
    Haematologica; 2008 Nov; 93(11):1658-65. PubMed ID: 18835836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of the glucocorticoid receptor and its isoforms in relation to glucocorticoid resistance in childhood acute lymphocytic leukemia.
    Tissing WJ; Lauten M; Meijerink JP; den Boer ML; Koper JW; Sonneveld P; Pieters R
    Haematologica; 2005 Sep; 90(9):1279-81. PubMed ID: 16154856
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vincristine pharmacokinetics and response to vincristine monotherapy in an up-front window study of the Dutch Childhood Leukaemia Study Group (DCLSG).
    Groninger E; Meeuwsen-de Boer T; Koopmans P; Uges D; Sluiter W; Veerman A; Kamps W; de Graaf S
    Eur J Cancer; 2005 Jan; 41(1):98-103. PubMed ID: 15617994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overt testicular disease (OTD) at diagnosis is not associated with a poor prognosis in childhood acute lymphoblastic leukemia: results of the EORTC CLG Study 58881.
    Sirvent N; Suciu S; Bertrand Y; Uyttebroeck A; Lescoeur B; Otten J
    Pediatr Blood Cancer; 2007 Sep; 49(3):344-8. PubMed ID: 16358303
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia.
    Yang L; Panetta JC; Cai X; Yang W; Pei D; Cheng C; Kornegay N; Pui CH; Relling MV
    J Clin Oncol; 2008 Apr; 26(12):1932-9. PubMed ID: 18421047
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of peanut agglutinin binding in childhood acute lymphoblastic leukemia.
    Kaspers GJ; Veerman AJ; Van Wering ER; Van Der Linden-Schrever BE; Van Zantwijk CH; Van Der Does-Van Den Berg A; Pieters R
    Leukemia; 1996 Apr; 10(4):675-81. PubMed ID: 8618446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.